CytomX Therapeutics (CTMX) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shattuck Labs (STTK) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 119.7% versus a loss of 47.7%. Over five years, STTK leads with a -52.0% price change compared with -69.9% for CTMX. Shattuck Labs is the larger company by market cap ($454.2 million vs $442.5 million), about 1.0 times the size, while CytomX Therapeutics is growing revenue faster (-44.8% vs -82.5%).
CytomX Therapeutics converts more of its revenue into profit, with a net margin of -22.8% versus -4880.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTMX | STTK |
|---|---|---|
| Share price | $2.03 | $4.46 |
| Market cap | $442.55M | $454.22M |
| 1-day change | -0.98% | -1.98% |
| YTD return | -52.35% | +22.19% |
| 1-year return | -47.68% | +119.70% |
| 5-year return | -69.93% | -51.99% |
| EPS (TTM) | $-0.51 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $76.20M | $1.00M |
| Revenue growth (YoY) | -44.82% | -82.52% |
| Net income (latest FY) | $-17.37M | $-48.81M |
| Operating margin | -29.35% | -5150.80% |
| Net margin | -22.79% | -4880.90% |
| 52-week high | $8.21 | $8.33 |
| 52-week low | $1.87 | $1.93 |
| Distance from 52-week high | -75.27% | -46.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +509.85% | +245.29% |
| Average volume | 4.27M | 1.20M |
| Shares outstanding | 218.00M | 101.84M |
| Employees | 69 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed CTMX by 167.4 percentage points over the past year.
- CytomX Therapeutics is more profitable, keeping -22.8 cents of every revenue dollar as net income versus -4880.9 cents for Shattuck Labs.
- CytomX Therapeutics grew revenue faster in its latest fiscal year (-44.82% vs -82.52%).
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
CTMX vs STTK FAQ
Which is bigger, CytomX Therapeutics or Shattuck Labs?
Shattuck Labs (STTK) is larger, with a market capitalization of $454.22M compared with $442.55M for CytomX Therapeutics (CTMX).
Which stock has performed better over the past year, CTMX or STTK?
STTK returned +119.70% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are CytomX Therapeutics and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.